Our Pipeline

---

Our lead drug candidate, GPS-491 blocks the replication of important viruses with unmet clinical need- Herpes, HIV, adenovirus, coronaviruses and other known and new emerging viruses. GPS491 modulates RNA processing and  is highly effective against SARS-CoV2 and common circulating coronaviruses. The multiple corona-viral strains, including emerging COVID-19 variants, which pose a risk for vaccine failure, require RNA processing and will therefore retain GPS-491 sensitivity.